Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wendling

Showing results (11-20 of 496) with videos related to

Pageof 50
Sort By:
Expert Opinion on Emerging Drugs|December 11, 2012
Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?Daniel Wendling
Expert Review of Clinical Immunology|October 31, 2013
Looking for the best target for biologic treatment of spondyloarthritisDaniel Wendling
Joint Bone Spine|November 21, 2022
Is psoriatic arthritis doomed to disappear?Daniel Wendling
Joint Bone Spine|May 3, 2022
Disc calcifications: Think of ochronosisDaniel Wendling
Drugs|October 10, 2024
Difficult-to-Treat Axial Spondyloarthritis: A New ChallengeDaniel Wendling
Expert Opinion on Investigational Drugs|November 13, 2015
An overview of investigational new drugs for treating ankylosing spondylitisDaniel Wendling
Rheumatology International|November 6, 2009
IL-23 and IL-17 in ankylosing spondylitisDaniel Wendling
Expert Review of Clinical Immunology|April 24, 2015
Treating to target in axial spondyloarthritis: defining the target and the arrowDaniel Wendling
Clinical Rheumatology|February 24, 2007
Surgery in rheumatoid arthritis patients under anti-TNF-alpha therapy: what is the risk?Daniel Wendling
The Journal of Rheumatology|July 5, 2005
Bone loss in ankylosing spondylitis: can we put the puzzle together?Daniel Wendling
Pageof 50

Showing results (11-20 of 496) with videos related to

Sort By:
Pageof 50
Expert Opinion on Emerging Drugs|December 11, 2012
Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?Daniel Wendling
Expert Review of Clinical Immunology|October 31, 2013
Looking for the best target for biologic treatment of spondyloarthritisDaniel Wendling
Joint Bone Spine|November 21, 2022
Is psoriatic arthritis doomed to disappear?Daniel Wendling
Joint Bone Spine|May 3, 2022
Disc calcifications: Think of ochronosisDaniel Wendling
Drugs|October 10, 2024
Difficult-to-Treat Axial Spondyloarthritis: A New ChallengeDaniel Wendling
Expert Opinion on Investigational Drugs|November 13, 2015
An overview of investigational new drugs for treating ankylosing spondylitisDaniel Wendling
Rheumatology International|November 6, 2009
IL-23 and IL-17 in ankylosing spondylitisDaniel Wendling
Expert Review of Clinical Immunology|April 24, 2015
Treating to target in axial spondyloarthritis: defining the target and the arrowDaniel Wendling
Clinical Rheumatology|February 24, 2007
Surgery in rheumatoid arthritis patients under anti-TNF-alpha therapy: what is the risk?Daniel Wendling
The Journal of Rheumatology|July 5, 2005
Bone loss in ankylosing spondylitis: can we put the puzzle together?Daniel Wendling
Pageof 50